More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over 180 cannabinoid-derivatives that target the human endocannabinoid signalling system
Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.
- An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations.
- An analysis of the partnerships that have been established in the recent past, covering acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other relevant types of deals.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, key value drivers, and financial details of the deal (if available). In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analysing them based on a number of parameters, namely annual revenues, number of employees and experience of the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this link
The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:
-
- Target Disease Indication
- Cancer
- Genetic Disorders
- Neurological Indications
- Others
- Route of Administration
- Oral
- Inhalation
- Key Geographies
- North America
- Europe
Asia-Pacific and the Rest of the World
The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:
- GW Pharmaceuticals
- Corbus Pharmaceuticals
- Tilray
- Tetra Bio-Pharma
- Botanix Pharmaceuticals
- Kalytera Therapeutics
- Therapix Biosciences
- Echo Pharmaceuticals
- Avicanna
- GB Sciences
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
5. COMPANY PROFILES
6. ACADEMIC GRANTS ANALYSIS
7. PARTNERSHIPS AND COLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. DRUG DEVELOPMENT STRATEGY ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415